{"name":"Aldeyra Therapeutics, Inc.","slug":"aldeyra-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Ophthalmology","slug":"ophthalmology","revenue":0,"percentOfTotal":0,"drugCount":7,"colorKey":"oncology","drugs":[{"name":"Active topical NS2 1% dermatologic cream","genericName":"Active topical NS2 1% dermatologic cream","slug":"active-topical-ns2-1-dermatologic-cream","indication":"Treatment of dry eye disease","status":"phase_2"},{"name":"ICM ADX-2191 injection","genericName":"ICM ADX-2191 injection","slug":"icm-adx-2191-injection","indication":"Dry eye disease","status":"phase_3"},{"name":"Monthly ADX-2191 injection","genericName":"Monthly ADX-2191 injection","slug":"monthly-adx-2191-injection","indication":"Dry eye disease","status":"phase_3"},{"name":"Vehicle Ophthalmic Solution QID","genericName":"Vehicle Ophthalmic Solution QID","slug":"vehicle-ophthalmic-solution-qid","indication":"Used as a control in clinical trials for ophthalmic conditions","status":"phase_3"},{"name":"Vehicle Ophthalmic Solution QID to BID","genericName":"Vehicle Ophthalmic Solution QID to BID","slug":"vehicle-ophthalmic-solution-qid-to-bid","indication":"Ophthalmic indication (specific indication not specified in available information)","status":"phase_3"},{"name":"Vehicle Opthalmic Solution","genericName":"Vehicle Opthalmic Solution","slug":"vehicle-opthalmic-solution","indication":"Treatment of dry eye disease","status":"phase_3"},{"name":"Vehicle of ADX-102 Ophthalmic Drops","genericName":"Vehicle of ADX-102 Ophthalmic Drops","slug":"vehicle-of-adx-102-ophthalmic-drops","indication":"Dry eye disease","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"ADX-2191","genericName":"ADX-2191","slug":"adx-2191","indication":"Proliferative vitreoretinopathy (PVR)","status":"phase_2"},{"name":"ADX-629","genericName":"ADX-629","slug":"adx-629","indication":"Other","status":"phase_2"}]},{"name":"Dermatology","slug":"dermatology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Vehicle of ADX-102 Topical Dermal Cream","genericName":"Vehicle of ADX-102 Topical Dermal Cream","slug":"vehicle-of-adx-102-topical-dermal-cream","indication":"Vernal keratoconjunctivitis","status":"phase_3"}]}],"pipeline":[{"name":"Active topical NS2 1% dermatologic cream","genericName":"Active topical NS2 1% dermatologic cream","slug":"active-topical-ns2-1-dermatologic-cream","phase":"phase_2","mechanism":"Active topical NS2 1% dermatologic cream works by targeting the underlying cause of inflammation in the skin.","indications":["Treatment of dry eye disease"],"catalyst":""},{"name":"ICM ADX-2191 injection","genericName":"ICM ADX-2191 injection","slug":"icm-adx-2191-injection","phase":"phase_3","mechanism":"ADX-2191 is a reactive aldehyde species that inhibits aldehyde dehydrogenase (ALDH) to modulate immune and inflammatory responses.","indications":["Dry eye disease","Ocular surface disease"],"catalyst":""},{"name":"ADX-2191","genericName":"ADX-2191","slug":"adx-2191","phase":"phase_2","mechanism":"ADX-2191 is designed to inhibit the activity of Rho-associated protein kinase (ROCK), which is involved in various cellular processes including inflammation and cell proliferation.","indications":["Proliferative vitreoretinopathy (PVR)"],"catalyst":""},{"name":"ADX-629","genericName":"ADX-629","slug":"adx-629","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Monthly ADX-2191 injection","genericName":"Monthly ADX-2191 injection","slug":"monthly-adx-2191-injection","phase":"phase_3","mechanism":"ADX-2191 is a reactive aldehyde species (RAS) scavenger that binds and neutralizes pathogenic aldehydes implicated in ocular surface inflammation and disease.","indications":["Dry eye disease","Ocular surface inflammation"],"catalyst":""},{"name":"Vehicle Ophthalmic Solution QID","genericName":"Vehicle Ophthalmic Solution QID","slug":"vehicle-ophthalmic-solution-qid","phase":"phase_3","mechanism":"Vehicle Ophthalmic Solution QID is a carrier solution used in clinical trials to deliver active drugs to the eye, without having a direct therapeutic effect itself.","indications":["Used as a control in clinical trials for ophthalmic conditions"],"catalyst":""},{"name":"Vehicle Ophthalmic Solution QID to BID","genericName":"Vehicle Ophthalmic Solution QID to BID","slug":"vehicle-ophthalmic-solution-qid-to-bid","phase":"phase_3","mechanism":"A vehicle ophthalmic solution formulation designed to be administered topically to the eye at varying frequencies (four times daily reduced to twice daily).","indications":["Ophthalmic indication (specific indication not specified in available information)"],"catalyst":""},{"name":"Vehicle Opthalmic Solution","genericName":"Vehicle Opthalmic Solution","slug":"vehicle-opthalmic-solution","phase":"phase_3","mechanism":"Vehicle Ophthalmic Solution is a non-medicated solution used to flush out the eye.","indications":["Treatment of dry eye disease"],"catalyst":""},{"name":"Vehicle of ADX-102 Ophthalmic Drops","genericName":"Vehicle of ADX-102 Ophthalmic Drops","slug":"vehicle-of-adx-102-ophthalmic-drops","phase":"phase_3","mechanism":"This is a vehicle formulation (inactive carrier system) for ADX-102, designed to deliver the active pharmaceutical ingredient to the ocular surface.","indications":["Dry eye disease","Allergic conjunctivitis"],"catalyst":""},{"name":"Vehicle of ADX-102 Topical Dermal Cream","genericName":"Vehicle of ADX-102 Topical Dermal Cream","slug":"vehicle-of-adx-102-topical-dermal-cream","phase":"phase_3","mechanism":"ADX-102 is a topical dermal cream that targets the complement pathway to reduce inflammation.","indications":["Vernal keratoconjunctivitis","Atopic keratoconjunctivitis"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMitAJBVV95cUxOUkZ6RmoyY3k1dmJfOUZQMHdjWmRlUDhoSEFMVmplZkgyT1ZSaUZ2czljWl9BQTJuY2FDZ3FXSUJhWEp2Q2t4MjNrYl8wRGZhWmdRUFNtWlR5cWxZM2c3V2QweWNJM0tUTzNlRXc3c1FJWnVoMVdrbXBsZnhFeF9Bd3ZKY1NPREcwbGtUbnppY3QwelN6TFZoNkNZWEt0WENZby1KdC16a2twSE1VdWFvZm9oaUN5Q1JuZzBMY256NUtDdDVZU21PZ0pXdENqRW5UbXpwc2U4QjE4TTBnTUZVS2lQOVRYbDE5dlNFZVNReFpWalhGYnhBWjBtODA2RzRTZWxWc1d2R21NN2c5bG1PMmF5YVkwUEtXeFF0MzNPbktfYkxxTHJteW1PaENjXzZmeUlwRA?oc=5","date":"2026-04-06","type":"pipeline","source":"GlobeNewswire","summary":"ADLX Class Action Notice: Robbins LLP Reminds Investors of - GlobeNewswire","headline":"ADLX Class Action Notice: Robbins LLP Reminds Investors of","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxPRks0dXMyOFh0MGlOdVhBclh6QTJUNW9UdGU0eFhiUXZ4TnV5WmZCbWpwUndfMTZLUXBxdm03UlNvU0h4RmlrSWJTOG5PQ1FMZHU2dldXZ1daY3Y1Mlk1cDdlemp1TC03MEFtaUxuMHZmWk85Y2hGcHhKakU3WGhVc2F1V2Y5aGR4Znhjc0FjS2RoTDAyU2hLNGJnMC1yeHVNWDBFa3dIYTMtaEpleHc1UG40ai0yTzJDQzQ1LWUzLXhCSk1fa3hxZExZOGM?oc=5","date":"2026-04-03","type":"pipeline","source":"National Today","summary":"ROSEN Attorneys Encourage Aldeyra Therapeutics Investors to Secure Counsel - National Today","headline":"ROSEN Attorneys Encourage Aldeyra Therapeutics Investors to Secure Counsel","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0gFBVV95cUxPaUhqaXRrVWZoOEVxZGJRTkVFUTdqNS1mTkZZZlpaeUZuUFFWMFVUYnZoTld3T3h6TlVjYkt2c3BOWnJxc3lYeXotb2M0aDJLSlVySnpHS25ydHVkV0xueldDYzhqLV9fZ2hrbENGdEdIQ3FTTTZyd0dINEhNQXBiUjduQ1lkX3NLRGFRV0tNUWkwQmFiREhEZ0FMRDNOQ0x3TDlsTHo0N0JUVm9DaF92ZGJuSzlCUXdHdU5USmNvUlpmNmlRRjNMcnA4TUE1SU42U2c?oc=5","date":"2026-03-31","type":"trial","source":"National Today","summary":"Lawsuit Filed Against Aldeyra Therapeutics Over Clinical Trial Inconsistencies - National Today","headline":"Lawsuit Filed Against Aldeyra Therapeutics Over Clinical Trial Inconsistencies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxNTXZBZmRERGlQWVBSTmU5LUZnSkRIUW5hZURjZnBrYjlvS2g2dmxIRnpxZjVSY2lMRlVka2k3Q2pLdW1FblllNDhsRWlfbVBLVHBHNnNkYkE3Z2pzQlNDT2NWMkZlX2NZVU1lbk1IdTVhSWk5MFBqamhIUEtxaUtLcl95YnBGTG9WUjZhaUVTUGhfMm5BMlZGQ1JhSFFDZ0FabUF4Tk9BWWhjd3NXU0pBUDFCZi0?oc=5","date":"2026-03-19","type":"pipeline","source":"Benzinga","summary":"12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga","headline":"12 Health Care Stocks Moving In Thursday's Intraday Session","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxPZHVYaHRsUDdOdVVHcXd2V1B4b3oxN2hVY3NxbEd5X3pIYmRqazE0TWJYOHd1bFBLN1hXaW11VEJ0Tm5ZYVM5Ylhxb2FzeFh1RmFxMTBJT20wYkVGX3RocmEyVS02Z3BCQkNfQ09kbVlCZTZ0WlBQSDFlVzAxNDJjRFFfY25oRkNHSC1FLUpNMXFjNFYzR1NvYU0zdTJ6V3F3c1NJeWVMdm9PSHFCYU9PWTBKel9Id1hLd1Y4d3JSWQ?oc=5","date":"2026-03-17","type":"regulatory","source":"Reuters","summary":"US FDA declines to approve Aldeyra's eye disorder drug, shares slump - Reuters","headline":"US FDA declines to approve Aldeyra's eye disorder drug, shares slump","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxPcEFjWERLem9GQnBoQURhZ1FNcXBfbWhDamg3RmJJV202NE9yN2pqT3RMbmlTdG5wOGtHNmtsbEN0YUpSc2FESXRzUVBXdnRfZVZxUTkwTGpVUDlqSmhySWYySjZSZEN2eEFhXy12ZWNSQlVLa2ZtYVV4cTFOcy05b1pzVEc2dWsyR1NMZDhB?oc=5","date":"2026-03-12","type":"pipeline","source":"statnews.com","summary":"Is Aldeyra Therapeutics waving red flags with consequences? - statnews.com","headline":"Is Aldeyra Therapeutics waving red flags with consequences?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE1qX2xyWklHeG9keGNHYWh6LUd4aXhvTThnUm83aEJUQUlHZ0c1WHVqc05GV005YUNpcDQwcm1TOHB6QWROYjZRVUxxM01zYzcyMXAw?oc=5","date":"2025-12-16","type":"regulatory","source":"FirstWord Pharma","summary":"FDA pushes back decision for Aldeyra's dry-eye therapy - FirstWord Pharma","headline":"FDA pushes back decision for Aldeyra's dry-eye therapy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxQNjdVTi1HaUF5TmtSOTlIY1QwY2VDNXRaRTN4ejVGZFlEaUEwYmhBdlg5SDNUaWhUUlplQVRqMDFEY0QyZFZ5ZW1JRUVqOWhsdW5UQkVFdXJVN184MzJpbGluclhPVjBiZnhwQTZrS2VFNTloejJSREFqMDUwMzB1NlJBbjBIb0NuajIzbkM0ZUo1R3hoM1dz?oc=5","date":"2025-12-02","type":"regulatory","source":"BioCentury","summary":"FDA’s docket holds 16 more PDUFA dates by year-end - BioCentury","headline":"FDA’s docket holds 16 more PDUFA dates by year-end","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxOWnN2VkQzYVUyOTJrQk8tcWRPVFkzejBZclZ0aXZlS195LWRLOVdaZ285MlBfWFFUbTZ6V3hiRlFtQUQtZ01QbVdPeWRibXc4VmtlcThtWk9TT1pSamFFcERzZ2xoTmNHMHVOTUU4V1N3TDE2TlhORldweTJBT2lqVzNOOHhFMEdr?oc=5","date":"2025-10-29","type":"regulatory","source":"The Business Journals","summary":"Three Boston biotechs await FDA decisions on new drugs by year-end - The Business Journals","headline":"Three Boston biotechs await FDA decisions on new drugs by year-end","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMieEFVX3lxTE1YUml2Q25KXzhVUExMOXdtQmduZ0JqNUFWaUE3a2FKOGp1ZVk0OHJsN2lTZHNDQUNyS0tNU2FpUEhGQTk5c3dSR211eXAzTGl6WlZTMXFXTlFkb3pCZ1pZTlg4U0ZSeklXN3pxUmF6WmxsZ2lGZERfNg?oc=5","date":"2025-07-16","type":"deal","source":"Yahoo Finance","summary":"5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats - Yahoo Finance","headline":"5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxNdGRBOUNWNTJWV0hTQlVhaWR0OS11ZVFsMkdfQWpJN01Xb2lFbWJmaTl5Q3d0V0gyZ2FmNTNoZ0N5NEZPaWc4cGhfZHVoY0E0Q0FXLXVZQ3RtXzJGd2RHVXcxSzZqelpOajRNRTJMUGdJbTZhUW9QcUpYSmM0MlR1LWNnT3pHdmVrN3p1amxfNGRKbWFsNV9HM1R3aUZnWkMwZ1NwcGtuWjV2ZU1KZ1U0RXRfaw?oc=5","date":"2025-06-11","type":"pipeline","source":"BioSpace","summary":"Biopharma Right of First Negotiation Not a Golden Ticket to M&A, Jefferies Finds - BioSpace","headline":"Biopharma Right of First Negotiation Not a Golden Ticket to M&A, Jefferies Finds","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxORVJPSGRxR3A5Z213QzBPWEc4MGZGQnpweXk2R0J1VEFxWEdwUkthbXNUdzZaU1QwY2ZGREgzT3FDdzJzTEJnZXprREtKRkRjRjl5Zzg5bWFDSkszMDJjZUg1UVlvdFQ3VGZQWWxpOVdHVGhXajY4TE5NS1UydHFRQV9ORmlwT1NBOWtPU3NuckJ4S1hISkIwMzJXdl9lUXpodHhzMTln?oc=5","date":"2025-04-07","type":"regulatory","source":"Contract Pharma","summary":"Aldeyra’s Dry Eye Drug Gets Another Rejection from the FDA - Contract Pharma","headline":"Aldeyra’s Dry Eye Drug Gets Another Rejection from the FDA","sentiment":"negative"}],"patents":[],"drugCount":10,"phaseCounts":{"phase_2":3,"phase_3":7},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}